{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T21:51:40Z","timestamp":1790200300735,"version":"4.1.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002322","name":"CAPES","doi-asserted-by":"publisher","award":["BEX 3132\/15-3"],"award-info":[{"award-number":["BEX 3132\/15-3"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.ejps.2018.05.030","type":"journal-article","created":{"date-parts":[[2018,5,31]],"date-time":"2018-05-31T23:48:41Z","timestamp":1527810521000},"page":"236-242","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["Intestinal permeability determinants of norfloxacin in Ussing chamber model"],"prefix":"10.1016","volume":"121","author":[{"given":"Cassiana","family":"Mendes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela C.","family":"Meirelles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos A.S.","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Ponchel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2018.05.030_bb0005","doi-asserted-by":"crossref","first-page":"3483","DOI":"10.1002\/jps.21233","article-title":"Fluoroquinolone efflux mediated by ABC transporters","volume":"97","author":"Alvarez","year":"2008","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2018.05.030_bb0010","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1023\/A:1016212804288","article-title":"A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability","volume":"12","author":"Amidon","year":"1995","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2018.05.030_bb0015","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ejpb.2007.12.012","article-title":"Specific permeability modulation of intestinal paracellular pathway by chitosan-poly(isobutylcyanoacrylate) core-shell nanoparticles","volume":"69","author":"Bravo-Osuna","year":"2008","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejps.2018.05.030_bb0020","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ijpharm.2008.12.026","article-title":"Solubility behavior and biopharmaceutical classification of novel high-solubility ciprofloxacin and norfloxacin pharmaceutical derivatives","volume":"371","author":"Breda","year":"2009","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2018.05.030_bb0025","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1007\/s11095-006-9041-2","article-title":"Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model","volume":"23","author":"Cao","year":"2006","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2018.05.030_bb0030","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1124\/dmd.31.11.1337","article-title":"Constitutive expression of various xenobiotic and endobiotic transporter mRNAs in the choroid plexus of rats","volume":"31","author":"Choudhuri","year":"2003","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2018.05.030_bb0035","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrd3028","article-title":"Membrane transporters in drug development","volume":"9","author":"Consortium","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejps.2018.05.030_bb0040","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ijpharm.2013.02.007","article-title":"Contribution of TRPV1 and multidrug resistance proteins in the permeation of capsaicin across different intestinal regions","volume":"445","author":"Duan","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2018.05.030_bb0045","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1124\/mol.105.016832","article-title":"Interaction of organic cations with a newly identified plasma membrane monoamine transporter","volume":"68","author":"Engel","year":"2005","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejps.2018.05.030_bb0050","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.ejps.2006.04.010","article-title":"Regional levels of drug transporters along the human intestinal tract: co-expression of ABC and SLC transporters and comparison with Caco-2 cells","volume":"29","author":"Englund","year":"2006","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2018.05.030_bb0055","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.addr.2012.09.042","article-title":"Intestinal drug transporters: An overview","volume":"65","author":"Estudante","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejps.2018.05.030_bb0060","series-title":"Drugs","article-title":"Guidance for industry: waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system","author":"FDA","year":"2000"},{"key":"10.1016\/j.ejps.2018.05.030_bb0065","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1124\/dmd.108.022285","article-title":"Involvement of intestinal uptake transporters in the absorption of azithromycin and clarithromycin in the rat","volume":"36","author":"Garver","year":"2008","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2018.05.030_bb0070","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/sj.clpt.6100056","article-title":"Intestinal drug transporter expression and the impact of grapefruit juice in humans","volume":"81","author":"Glaeser","year":"2007","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2018.05.030_bb0075","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1177\/1087057105276034","article-title":"The advantages of the ussing chamber in drug absorption studies","volume":"10","author":"Gotoh","year":"2005","journal-title":"J. Biomol. Screen."},{"key":"10.1016\/j.ejps.2018.05.030_bb0080","doi-asserted-by":"crossref","first-page":"232","DOI":"10.2133\/dmpk.DMPK-11-RG-089","article-title":"Peptide cotransporter 1 in intestine and organic anion transporters in kidney are targets of interaction between JBP485 and Lisinopril in rats","volume":"27","author":"Guo","year":"2012","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.ejps.2018.05.030_bb0085","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1080\/00498250801986951","article-title":"Xenobiotic transporters of the human organic anion transporting polypeptides (OATP) family","volume":"38","author":"Hagenbuch","year":"2008","journal-title":"Xenobiotica"},{"key":"10.1016\/j.ejps.2018.05.030_bb0090","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1124\/mol.112.084517","article-title":"Organic cation transporter 1 (OCT1\/mOct1) is localized in the apical membrane of Caco-2 cell monolayers and enterocytes","volume":"84","author":"Han","year":"2013","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejps.2018.05.030_bb0095","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1002\/jcph.1088","article-title":"Core entrustable professional activities in clinical pharmacology: pearls for clinical practice: drug-drug and food-drug interactions","volume":"58","author":"Hermann","year":"2018","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2018.05.030_bb0100","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1016\/j.bbamem.2006.07.002","article-title":"Mechanism of the inhibitory effect of zwitterionic drugs (levofloxacin and grepafloxacin) on carnitine transporter (OCTN2) in Caco-2 cells","volume":"1758","author":"Hirano","year":"2006","journal-title":"Biochim. Biophys. Acta Biomembr."},{"key":"10.1016\/j.ejps.2018.05.030_bb0105","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1021\/mp100130b","article-title":"Intestinal absorption mechanism of tebipenem pivoxil, a novel oral carbapenem: involvement of human OATP family in apical membrane transport","volume":"7","author":"Kato","year":"2010","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejps.2018.05.030_bb0110","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1002\/jps.20075","article-title":"Combined application of parallel artificial membrane permeability assay and Caco-2 permeability assays in drug discovery","volume":"93","author":"Kerns","year":"2004","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2018.05.030_bb0115","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1021\/mp050084o","article-title":"Transporters and drug discovery: why, when, and how","volume":"3","author":"Kim","year":"2006","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejps.2018.05.030_bb0120","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1124\/dmd.110.034991","article-title":"Role of organic anion-transporting polypeptides for cellular mesalazine (5-aminosalicylic acid) uptake","volume":"39","author":"K\u00f6nig","year":"2011","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2018.05.030_bb0125","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.addr.2007.06.016","article-title":"Animal data: the contributions of the Ussing chamber and perfusion systems to predicting human oral drug delivery in vivo","volume":"59","author":"Lennern\u00e4s","year":"2007","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejps.2018.05.030_bb0130","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1021\/mp4003392","article-title":"Human in vivo regional intestinal permeability: importance for pharmaceutical drug development","volume":"11","author":"Lennern\u00e4s","year":"2014","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejps.2018.05.030_bb0135","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1440-1681.2009.05252.x","article-title":"Multidrug resistance-associated proteins and implications in drug development","volume":"37","author":"Liu","year":"2010","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"10.1016\/j.ejps.2018.05.030_bb0140","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1021\/mp060082j","article-title":"Identification of influx transporter for the quinolone antibacterial agent levofloxacin","volume":"4","author":"Maeda","year":"2007","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejps.2018.05.030_bb0145","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1586\/14787210.2015.982092","article-title":"Investigation of \u03b2-cyclodextrin-norfloxacin inclusion complexes. Part 2. Inclusion mode and stability studies","volume":"13","author":"Mendes","year":"2015","journal-title":"Expert Rev. Anti-Infect. Ther."},{"key":"10.1016\/j.ejps.2018.05.030_bb0150","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.2116\/analsci.31.1083","article-title":"Quantitative analysis of norfloxacin in \u00df-cyclodextrin inclusion complexes-development and validation of a stability-indicating HPLC method","volume":"31","author":"Mendes","year":"2015","journal-title":"Anal. Sci."},{"key":"10.1016\/j.ejps.2018.05.030_bb0155","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1124\/dmd.105.008219","article-title":"Breast cancer resistance protein (BCRP\/ABCG2) transports fluoroquinolone antibiotics and affects their oral availability, pharmacokinetics, and milk secretion","volume":"34","author":"Merino","year":"2006","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2018.05.030_bb0160","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1016\/j.dmpk.2017.11.192","article-title":"Global proteomic analysis of transporter proteins in the human small intestine and established intestinal cell lines","volume":"33","author":"M\u00fcller","year":"2018","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.ejps.2018.05.030_bb0165","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1128\/AAC.46.2.344-349.2002","article-title":"Involvement of multidrug resistance-associated protein 2 in intestinal secretion of grepafloxacin in rats","volume":"46","author":"Naruhashi","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejps.2018.05.030_bb0170","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/j.1552-4604.1988.tb05740.x","article-title":"The quinolones: an overview and comparative appraisal of their pharmacokinetics and pharmacodynamics","volume":"28","author":"Nix","year":"1988","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2018.05.030_bb0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/chromsci\/47.9.739","article-title":"Liquid chromatographic determination of norfloxacin in extended-release tablets","volume":"47","author":"Oliveira","year":"2009","journal-title":"J. Chromatogr. Sci."},{"key":"10.1016\/j.ejps.2018.05.030_bb0180","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.xphs.2015.11.040","article-title":"Why does the intestine lack basolateral efflux transporters for cationic compounds? A provocative hypothesis","volume":"105","author":"Proctor","year":"2016","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2018.05.030_bb0185","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.jnutbio.2008.07.012","article-title":"Carnitine synthesis and uptake into cells are stimulated by fasting in pigs as a model of nonproliferating species","volume":"20","author":"Ringseis","year":"2009","journal-title":"J. Nutr. Biochem."},{"key":"10.1016\/j.ejps.2018.05.030_bb0190","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ejps.2012.02.025","article-title":"Human small intestinal and colonic tissue mounted in the Ussing chamber as a tool for characterizing the intestinal absorption of drugs","volume":"46","author":"Rozehnal","year":"2012","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2018.05.030_bb0195","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.ejps.2012.10.007","article-title":"Comprehensive study on regional human intestinal permeability and prediction of fraction absorbed of drugs using the Ussing chamber technique","volume":"48","author":"Sj\u00f6berg","year":"2013","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2018.05.030_bb0200","doi-asserted-by":"crossref","first-page":"848","DOI":"10.4067\/S0717-97072011000400005","article-title":"In-vitro interaction studies of verapamil with fluoroquinolones using first order derivative UV spectrophotometry and RP-HPLC","volume":"56","author":"Sultana","year":"2011","journal-title":"J. Chil. Chem. Soc."},{"key":"10.1016\/j.ejps.2018.05.030_bb0205","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.pharmthera.2005.06.005","article-title":"Expression and function of efflux drug transporters in the intestine","volume":"109","author":"Takano","year":"2006","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2018.05.030_bb0210","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s004240000339","article-title":"Structural requirements for determining the substrate affinity of peptide transporters PEPT1 and PEPT2","volume":"440","author":"Terada","year":"2000","journal-title":"Pflugers Arch. - Eur. J. Physiol."},{"key":"10.1016\/j.ejps.2018.05.030_bb0215","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S0022-3565(25)22555-1","article-title":"Toxicity of cephaloridine to carnitine transport and fatty acid metabolism in rabbit renal cortical mitochondria: structure-activity relationships","volume":"270","author":"Tune","year":"1994","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejps.2018.05.030_bb0220","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1021\/mp900013d","article-title":"Disposition of naringenin via glucuronidation pathway is affected by compensating efflux transporters of hydrophilic glucuronides","volume":"6","author":"Xu","year":"2009","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejps.2018.05.030_bb0225","doi-asserted-by":"crossref","first-page":"787","DOI":"10.2174\/138920007782798171","article-title":"Multidrug resistance associated proteins as determining factors of pharmacokinetics and pharmacodynamics of drugs","volume":"8","author":"Yu","year":"2007","journal-title":"Curr. Drug Metab."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098718302550?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098718302550?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T11:49:10Z","timestamp":1760528950000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098718302550"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":45,"alternative-id":["S0928098718302550"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2018.05.030","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intestinal permeability determinants of norfloxacin in Ussing chamber model","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2018.05.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}